vTv Therapeutics to Host Investor Call and Announce Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 – Potential First-in-Class Oral Adjunctive Therapy for Patients with Type...
vTv Therapeutics Inc. - Class A (VTVT)
Last vtv therapeutics inc. - class a earnings: 7/31 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vtvtherapeutics.com
Company Research
Source: GlobeNewswire
HIGH POINT, N.C., Feb. 07, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that it will release the topline results from Part 2 of the Phase 2 Simplici-T1 trial assessing TTP399 as an oral adjunctive therapy to insulin in adults with type 1 diabetes (T1D) on Monday, February 10th at 7:00am ET. vTv Therapeutics’ leadership team will then host an investor conference call that day at 8:30am ET. In June 2019, the company announced positive results from Part 1 of the Phase 2 study that showed a statistically significant reduction in HbA1c without increases in ketoacidosis or hypoglycemia. In Part 1, TTP399 was well tolerated with similar incidences of treatment-emergent adverse events overall and by system organ class. Part 1 had no serious adverse event reported, and no report of diabetic ketoacidosis or severe hypoglycemia. Investor Call and Webcast Dial-In Information Domestic: 877-423-9813 International: 201-689-8573 Conference ID: 13699047 W
Show less
Read more
Impact Snapshot
Event Time:
VTVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTVT alerts
High impacting vTv Therapeutics Inc. - Class A news events
Weekly update
A roundup of the hottest topics
VTVT
News
- Diabetes Pipeline Landscape Research Report 2024: Comprehensive Insights About 200+ Companies and 200+ Pipeline Drugs [Yahoo! Finance]Yahoo! Finance
- vTv Therapeutics (NASDAQ:VTVT) adds US$9.5m to market cap in the past 7 days, though investors from five years ago are still down 71% [Yahoo! Finance]Yahoo! Finance
- vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate UpdateGlobeNewswire
- Marsh breaks ground on expansion [Yahoo! Finance]Yahoo! Finance
VTVT
Sec Filings
- 11/19/24 - Form 4
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- VTVT's page on the SEC website